9 results about "Henipavirus" patented technology

The present invention relates to a vaccine composition comprising a recombinant Nipah virus protein. The vaccine composition according to the present invention not only exhibits excellent immunogenicity against both the G protein and the F protein of Nipah virus, but also exhibits immunogenicity against the G protein and the F protein of Hendra virus, and thus can be used as a universal vaccine against Henipavirus. In addition, the vaccine composition has the characteristic of inducing cell-mediated immune responses, and therefore can be provided as a formulation for enhancing specific immune responses to an administered drug such as an adjuvant or a vaccine.

The invention provides a Hunipah virus mRNA vaccine as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The mRNA vaccine provided by the invention comprises mRNA attached to glycoprotein of a full-length Hendea virus and an mRNA vaccine delivery system, and serological analysis and a Nipah virus-Malaysia strain and Hendea virus challenge protection experiment prove that the vaccine provided by the invention can generate a very good immune protection effect only by immunizing two doses; the mRNA vaccine has effectiveness on a Nipah virus-Malaysia strain and a Hendea virus at the same time, can protect a subject from lethal infection of the Nipah virus-Malaysia strain and the Hendea virus, and is good in broad spectrum.

The disclosure provides a composition comprising at least two antibodies, wherein each antibody is a human or humanized antibody which binds to henipavirus F protein (an anti-henipavirus-F antibody).

Disclosed herein are antibodies or antigen binding fragments thereof that specifically bind human CD8. Also disclosed are fusion proteins comprising a Henipavirus glycoprotein G and CD8 antibodies for targeting and transducing cells expressing CD8. Viral vectors and other compositions containing the fusion proteins, as well as methods of using the fusion proteins, are also disclosed.

This application discloses a human monoclonal antibody against Hennipa virus and its preparation and application as a bispecific antibody. By screening memory B cells in fully human antibody-transgenic mice that specifically bind to Nipah virus glycoproteins (G and F proteins), human monoclonal antibodies 14B8 (targeting the F protein) and 4B8 (targeting the G protein) were obtained. Simultaneously, a bispecific antibody 14B8-IgG-4B8-scFv was constructed based on the above antibodies, which is formed by fusing the full antibody (IgG) of 14B8 with a single-chain antibody fragment of 4B8. Experiments demonstrated that the above antibodies exhibit extremely high binding affinity and neutralizing activity against NiV and HeV, and provide excellent in vivo protective efficacy in the LVG Golden Hamster model.

The application discloses a vaccine composition containing a recombinant G protein of Hendra virus. Specifically, a multimer and a monomer are constructed by using the recombinant G protein of Hendra virus, and a better in-vivo protection effect than DNA is obtained; and the construction of the tandem protein also effectively solves the problem of poor broad-spectrum property of the vaccine. Meanwhile, the in-vivo protection effect evaluation of the vaccine can be quickly and safely realized by detecting the fluorescence residue in the mouse in-vivo through a VSV pseudovirus live imaging model.

Provided herein are recombinant targeting polypeptides. Some such polypeptides include an external region comprising a CD2 binding domain such as a CD58 extracellular domain, a transmembrane region, and an internal region comprising a cytoplasmic fragment of a henipavirus G protein. Some embodiments relate to a viral particle that includes a recombinant targeting polypeptide. Also disclosed are methods of using the recombinant targeting polypeptides or viral particles comprising them.

The invention discloses a primer group, a kit and a verification method for detecting a Langheng nipah virus, the primer group comprises a primer group A for detecting the Langheng nipah virus and a primer group B for detecting the Langheng nipah virus, the primer group A comprises at least one of a primer group N, a primer group M and a primer group P / V / W / C; the primer group B comprises at least one of a primer group sg-N, a primer group sg-M, a primer group sg-L, a primer group sg-P / V / W / C-1 and a primer group sg-P / V / W / C-2. Primers are designed based on a plurality of conserved regions (including an N region, an M region and a P / V / W / C region) in a Langheng nipah virus genome, multi-target detection is realized, false negative caused by mutation of a single target is effectively avoided, and the sensitivity is improved.

Provided is an anti-Henipavirus monoclonal antibody having broad spectrum neutralization activity, wherein the antibody comprises a macaque variable region and a human constant region. The antibody of the present invention has good binding activity to both Nipah virus glycoprotein G and Hendra virus glycoprotein G, can effectively neutralize Nipahpseudovirus and Hendra pseudovirus, and can be used for preparing drugs for treating Henipavirus diseases.